Biomolecules & Therapeutics
Recent Advances of Therapeutic Targets for the Treatment of Periodontal Disease
Woo Jin Kim1, Yunjo Soh2,* and Seok-Mo Heo3,4,*
1Department of Molecular Genetics, School of Dentistry and Dental Research Institute, Seoul National University, Seoul 03080,
2Laboratory of Pharmacology, School of Pharmacy and Institute of New Drug Development, Jeonbuk National University, Jeonju 54896,
3Department of Periodontology, School of Dentistry, Jeonbuk National University, Jeonju 54896,
4Research Institute of Clinical Medicine of Jeonbuk National University, Jeonju 54907, Republic of Korea
*E-mail: (Heo SM), (Soh Y)
Tel: +82-63-250-2018 (Heo SM), +82-63-270-4038 (Soh Y)
Fax: +82-63-250-2259 (Heo SM), +82-63-270-4038 (Soh Y)
Received: January 4, 2021; Revised: January 25, 2021; Accepted: January 29, 2021; Published online: March 17, 2021.
© The Korean Society of Applied Pharmacology. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Periodontal disease is primarily associated with bacterial infection such as dental plaque. Dental plaque, an oral biofilm harboring a complex microbial community, can cause various inflammatory reactions in periodontal tissue. In many cases, the local bacterial invasion and host-mediated immune responses lead to severe alveolar bone destruction. To date, plaque control, non-surgical, and surgical interventions have been the conventional periodontal treatment modalities. Although adjuvant therapies including antibiotics or supplements have accompanied these procedures, their usage has been limited by antibiotic resistance, as well as their partial effectiveness. Therefore, new strategies are needed to control local inflammation in the periodontium and host immune responses. In recent years, target molecules that modulate microbial signaling mechanisms, host inflammatory substances, and bone immune responses have received considerable attention by researchers. In this review, we introduce three approaches that suggest a way forward for the development of new treatments for periodontal disease; (1) quorum quenching using quorum sensing inhibitors, (2) inflammasome targeting, and (3) use of FDA-approved anabolic agents, including Teriparatide and sclerostin antibody.
Keywords: Quorum sensing and quenching, Inflammasome, Teriparatide, Sclerostin antibody, Periodontitis, Parathyroid hormone

This Article

Cited By Articles
  • CrossRef (0)